Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmedical mutual - ohio Isturisa Prior Auth Coverage…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Isturisa (osilodrostat) prior authorization for Cushing's disease

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines recommended prior authorization criteria, documentation, and approval durations for Isturisa (osilodrostat) for adult patients with endogenous Cushing's syndrome/Cushing's disease when surgery is not an option or not curative. Affects prescribers and payers managing pharmacy benefit coverage.

    Policy Summary
    Payermedical mutual - ohio
    PolicyIsturisa (osilodrostat) prior authorization for Cushing's disease
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateApr 16, 2026
    Last ReviewApr 16, 2026
    Next Review DateApr 16, 2026
    Key ActionSubmit prior authorization and ensure Isturisa is prescribed by or in consultation with an endocrinologist and baseline labs (UFC, potassium, magnesium) are documented.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+minimum patient age for coverage
    6 moinitial approval duration
    1 yrextended approval duration
    elevated UFCbaseline UFC requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Recommended Authorization Criteria

    inv-11: Initial therapy requirements — Initial therapy eligibility for endogenous Cushing's syndrome

    Initial therapy eligibility for endogenous Cushing's syndrome

    Initial: Patient >=18; one of surgical/awaiting surgery/awaiting radiotherapy response; prescribed by/with endocrinologist or specialist; baseline elevated urinary free cortisol; baseline labs including potassium and magnesium completed

    inv-12: Continuation therapy requirements — Criteria for patients currently receiving Isturisa for at least 6 months

    Criteria for patients currently receiving Isturisa for at least 6 months

    Continuation: Patient >=18; meets one of B options regarding surgery/radiotherapy; Isturisa prescribed by/with an endocrinologist or specialist in Cushing's syndrome; documentation of positive response to therapy as decreased urinary free cortisol from baseline>=6 months on therapy

    Coverage is not recommended for circumstances that are not explicitly listed in the Recommended Authorization Criteria. The policy states that Isturisa has not been shown to be effective, or has limited/preliminary data or potential safety concerns, for certain conditions and that the list of Conditions Not Recommended for Approval is not exhaustive. Criteria will be updated as new published data become available.

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Prior authorization required for Isturisa

    Prior authorization is recommended for pharmacy benefit coverage of Isturisa. Initial approval requires the drug be prescribed by or in consultation with a physician who specializes in the condition being treated; approvals for initial therapy are provided for the initial approval duration and reauthorization requires documented response to therapy when applicable.

    • Prior authorization recommended for pharmacy benefit coverage of Isturisa.
    • Initial prescriptions must be by or in consultation with an endocrinologist or specialist in Cushing's syndromes.
    • Initial approvals are for the initial approval duration; reauthorization generally requires evidence of response.
    Step Therapy

    No step therapy required

    No step therapy sequence is specified in this policy; the document does not require trial of alternative agents prior to approval.

    Therapy Duration and Coding Notes

    inv-04: Duration on therapy for continuation
    Continuation durationPatient must have been receiving Isturisa for at least 6 months
    Age requirementPatient is 18 years of age or older
    Prescriber requirementIsturisa prescribed by or in consultation with an endocrinologist or specialist in Cushing's syndrome
    Evidence of responseDocumentation of decreased urinary free cortisol from baseline required for continuation
    Surgical statusPatient must meet one of: not a candidate for surgery/not curative; awaiting surgery; or awaiting radiotherapy response

    Clinical Definitions

    inv-10: Endogenous Cushing's syndrome / Cushing's disease
    DefinitionEndogenous overproduction of cortisol; Cushing's disease (pituitary source) is included within endogenous Cushing's syndrome for the purposes of these criteria
    FDA-approved indication (context)Isturisa is indicated for adult patients with Cushing's disease when pituitary surgery is not an option or has not been curative
    Typical clinical featuresBaseline urinary free cortisol elevated required for initiation; monitoring of UFC used to document response
    Age scopeApplies to adult patients (>=18 years)

    Drug Background

    Isturisa (osilodrostat) is a cortisol synthesis inhibitor that blocks cortisol formation by inhibiting 11-beta-hydroxylase and is FDA-approved for adults with endogenous Cushing's syndrome/Cushing's disease when pituitary surgery is not an option or has not been curative. It is used both as initial therapy when surgery is not possible or curative or while awaiting surgery or the effect of radiotherapy, and for patients currently receiving therapy with demonstrated response.

    Policy Summary
    Payermedical mutual - ohio
    PolicyIsturisa (osilodrostat) prior authorization for Cushing's disease
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateApr 16, 2026
    Last ReviewApr 16, 2026
    Next Review DateApr 16, 2026
    Key ActionSubmit prior authorization and ensure Isturisa is prescribed by or in consultation with an endocrinologist and baseline labs (UFC, potassium, magnesium) are documented.
    SourceLink
    On This Page
    Recommended Authorization CriteriaPrior Authorization and Documentation RequirementsTherapy Duration and Coding NotesClinical DefinitionsDrug Background
  1. Step therapy: Not specified in the policy.
  2. Documentation Required

    Documentation the payer may request

    The Company may request additional documentation to support coverage decisions; providers must make requested records and supporting information available upon request.

    • Documentation that may be requested includes patient records and test results (e.g., baseline urinary free cortisol, serum potassium, serum magnesium).
    • Provider credentials or documentation of consultation with a specialist may be requested.
    • Additional documentation supporting medical necessity must be provided upon request.
    Denial Risk

    Denial risks and required documentation

    The Company may deny reimbursement if the drug or services are determined not medically necessary, investigational/experimental, outside member benefits, or if inappropriate/excessive billing or insufficient documentation is identified.

    • Denial risks include lack of medical necessity, investigational/experimental use, not within member benefits, or patterns of inappropriate/excessive billing.
    • Insufficient supporting documentation (e.g., missing baseline UFC or baseline labs) may lead to denial.